Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Surg Today. 2010 Apr;40(4):287-94. doi: 10.1007/s00595-009-4152-0. Epub 2010 Mar 26.
The prognosis of patients with liver metastasis from gastric cancer is dismal. This article reviews the characteristics of gastric cancer metastasizing to the liver, and multimodality of treatments. Differentiated adenocarcinoma, poorly differentiated adenocarcinoma with a medullary growth pattern, and special types, including endocrine carcinoma and hepatoid carcinoma, are likely to metastasize to the liver. The overexpression of growth factors or adhesion molecules is clinically significant for liver metastasis. Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if a complete resection seems feasible after careful preoperative staging. A hepatic resection should always be considered as an option for gastric cancer patients with hepatic metastases. Newer generation cytotoxic agents such as S-1, irinotecan, and taxanes show promising activity for patients with metastases. Adjuvant chemotherapy or molecular targeted therapy will provide significant benefits to patients in the future.
胃转移癌患者的预后较差。本文回顾了胃癌肝转移的特点和多种治疗方法。分化型腺癌、具有髓样生长模式的低分化腺癌和特殊类型,包括内分泌癌和肝样癌,可能会转移到肝脏。生长因子或黏附分子的过度表达对肝转移具有临床意义。如果仔细的术前分期后认为完全切除是可行的,那么胃腺癌肝转移的手术治疗是合理的。对于有肝转移的胃癌患者,肝切除术应始终作为一种选择。新一代细胞毒药物如替吉奥、伊立替康和紫杉烷类药物对转移性患者具有良好的疗效。辅助化疗或分子靶向治疗将为患者带来显著获益。